Newsroom
Our latest developments
Orca Bio’s announcements and press releases
Orca Bio Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Orca-Q® for the Treatment of High-Risk Hematologic Malignancies
ViewOrca Bio Announces FDA Review Extension of BLA for Orca-T for the Treatment of Hematologic Malignancies
ViewOrca Bio to Present Clinical Data on Its Pipeline of High-Precision Cell Therapies at the 52nd Annual Meeting of the EBMT
ViewOrca Bio Presents New Data at the 2026 Tandem Meetings of ASTCT® and CIBMTR® Reinforcing Orca-T® as a Durable, High-Precision Cell Therapy for Hematological Malignancies
ViewOrca Bio to Present New Clinical Data on Its High-Precision Cell Therapies at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
ViewOrca Bio Announces $250M in Aggregate Financing in Preparation for Potential Commercialization
ViewOrca Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
ViewOrca Bio's fact sheets
Orca Bio Corporate Overview
View